Mindfulness and other behavioral approaches
- PMID: 35624359
- DOI: 10.1007/s10072-022-06155-z
Mindfulness and other behavioral approaches
Abstract
Mindfulness and other behavioral approaches have demonstrated efficacy in treatment of different kinds of chronic pain condition and migraine in particular. Such treatments are of particular utility in the treatment of chronic forms of migraine, also associated to medication overuse headache, in reason of the relevant comorbidity - and bidirectional relationship - between migraine, and two of the most common associated conditions, namely anxiety and depression. Second, in reason of the impact that such treatments may have on behavioral issues that might promote MOH maintenance, including external locus of control and self-efficacy. Although the specific mechanism of action of these approaches has not been clarified yet, the absence of side effects and their effectiveness make these options suitable for different categories of frail patients and also for patients during therapy with medication if we want to improve the efficacy of medications itself. The use of these approaches has to be encouraged for clinicians and for patients to treat at the best pain condition and migraine and to improve the efficacy of the new medication for migraine prevention.
Keywords: Behavioral approach; Migraine; Mindfulness.
© 2022. Fondazione Società Italiana di Neurologia.
References
-
- Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202
-
- Raggi A, Grignani E, Leonardi M, Andrasik F, Sansone E, Grazzi L, D’Amico D (2018) Behavioral approaches for primary headaches: recent advances. Headache 58(6):913–925. https://doi.org/10.1111/head.13337 - DOI - PubMed
-
- Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2128544. https://doi.org/10.1001/jamanetworkopen.2021.28544 - DOI - PubMed - PMC
-
- Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ (2021) Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 97(10268):51–60. https://doi.org/10.1016/S0140-6736(20)32544-7 - DOI
-
- Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol 19(9):727–737. https://doi.org/10.1016/S1474-4422(20)30234-9 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical